Burlington Stores Free cash flow decreased by 131.6% to -$227.26M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.2%, from -$438.61M to -$227.26M. Over 2 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -40.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $151.74M | $127.95M | $90.22M | $110.79M | -$279.20M | -$82.44M | $32.24M | $478.39M | -$173.64M | $410.34M | -$115.47M | -$35.17M | -$56.22M | -$438.61M | -$101.00K | -$109.62M | $719.92M | -$227.26M |
| QoQ Change | — | -15.7% | -29.5% | +22.8% | -352.0% | +70.5% | +139.1% | >999% | -136.3% | +336.3% | -128.1% | +69.5% | -59.9% | -680.1% | +100.0% | <-999% | +756.7% | -131.6% |
| YoY Change | — | — | — | — | -284.0% | -164.4% | -64.3% | +331.8% | +37.8% | -14.2% | +33.5% | — | — | -279.9% | +99.7% | -95.0% | — | +48.2% |